Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodney Dawson

Showing results (61-70 of 94) with videos related to

Pageof 10
Sort By:
Antimicrobial Agents and Chemotherapy|September 28, 2023
Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosisRalf Stemkens, Veronique de Jager, Rodney Dawson, et al.
The Lancet. Respiratory Medicine|January 17, 2014
Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatmentSven O Friedrich, Andrea Rachow, Elmar Saathoff, et al.
Lancet (London, England)|March 22, 2015
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosisRodney Dawson, Andreas H Diacon, Daniel Everitt, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 13, 2024
Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With HIV From 6 CountriesN Sarita Shah, Cissy Kityo, Michael D Hughes, et al.
BMC Medicine|March 30, 2018
Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB studyConor Duncan Tweed, Genevieve Helen Wills, Angela M Crook, et al.
American Journal of Respiratory and Critical Care Medicine|August 18, 2015
A Step toward an Optimized Rifampin Dose CompletedMartin J Boeree, Andreas H Diacon, Rodney Dawson, et al.
BMC Infectious Diseases|July 13, 2018
Toxicity associated with tuberculosis chemotherapy in the REMoxTB studyConor D Tweed, Angela M Crook, Evans I Amukoye, et al.
American Journal of Respiratory and Critical Care Medicine|February 6, 2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosisMartin J Boeree, Andreas H Diacon, Rodney Dawson, et al.
The Lancet. Respiratory Medicine|November 17, 2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trialConor D Tweed, Rodney Dawson, Divan A Burger, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 20, 2018
The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary TuberculosisElin M Svensson, Robin J Svensson, Lindsey H M Te Brake, et al.
Pageof 10

Showing results (61-70 of 94) with videos related to

Sort By:
Pageof 10
Antimicrobial Agents and Chemotherapy|September 28, 2023
Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosisRalf Stemkens, Veronique de Jager, Rodney Dawson, et al.
The Lancet. Respiratory Medicine|January 17, 2014
Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatmentSven O Friedrich, Andrea Rachow, Elmar Saathoff, et al.
Lancet (London, England)|March 22, 2015
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosisRodney Dawson, Andreas H Diacon, Daniel Everitt, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 13, 2024
Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With HIV From 6 CountriesN Sarita Shah, Cissy Kityo, Michael D Hughes, et al.
BMC Medicine|March 30, 2018
Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB studyConor Duncan Tweed, Genevieve Helen Wills, Angela M Crook, et al.
American Journal of Respiratory and Critical Care Medicine|August 18, 2015
A Step toward an Optimized Rifampin Dose CompletedMartin J Boeree, Andreas H Diacon, Rodney Dawson, et al.
BMC Infectious Diseases|July 13, 2018
Toxicity associated with tuberculosis chemotherapy in the REMoxTB studyConor D Tweed, Angela M Crook, Evans I Amukoye, et al.
American Journal of Respiratory and Critical Care Medicine|February 6, 2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosisMartin J Boeree, Andreas H Diacon, Rodney Dawson, et al.
The Lancet. Respiratory Medicine|November 17, 2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trialConor D Tweed, Rodney Dawson, Divan A Burger, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 20, 2018
The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary TuberculosisElin M Svensson, Robin J Svensson, Lindsey H M Te Brake, et al.
Pageof 10